This approach employs engineered fusion proteins that integrate a blue light-responsive domain (such as CRY2 or LOV) with the low complexity region of neurodegenerative markers like TDP-43, alpha-synuclein, or Tau. In the absence of light, these chimeric proteins remain soluble within the cellular environment; however, upon exposure to blue light, the photoreceptor domains induce rapid clustering and aggregation. This controlled process accurately replicates key pathological features observed in neurodegenerative conditions, including cytoplasmic mislocalization, hyperphosphorylation, ubiquitination, and cleavage, all without modifying protein expression levels. The system supports spatial and temporal precision in modeling disease states across various in vitro and in vivo platforms and offers robust potential for high-throughput screening.
Description
The method is distinguished by its non-invasive, externally controlled mechanism that bypasses the need for protein overexpression or the introduction of specific disease mutations. Its capacity to mimic authentic protein aggregation dynamics closely aligns with patient pathology, thereby bridging the gap between conventional models and the underlying biology of neurodegenerative diseases. This specificity and versatility make it an invaluable tool for both detailed mechanistic studies and the discovery of novel therapeutic strategies.
Applications
- High-throughput drug screening
- In vivo disease model creation
- Antibody generation for diagnostics
- Neurodegenerative research tools
Advantages
- Provides precise spatial and temporal control of protein aggregation through light stimulation.
- Replicates key neurodegenerative disease hallmarks without relying on genetic mutations or overexpression.
- Enables real-time modeling and study of disease progression in both in vitro and in vivo systems.
- Supports high-throughput screening of therapeutic compounds to modulate protein aggregation and toxicity.
- Facilitates the development of versatile disease models for basic research and translational applications.
Invention Readiness
Currently in vitro data stage.
IP Status
https://patents.google.com/patent/WO2018165293A1
